US3784688A - Anti-anxiety combination - Google Patents

Anti-anxiety combination Download PDF

Info

Publication number
US3784688A
US3784688A US00190691A US3784688DA US3784688A US 3784688 A US3784688 A US 3784688A US 00190691 A US00190691 A US 00190691A US 3784688D A US3784688D A US 3784688DA US 3784688 A US3784688 A US 3784688A
Authority
US
United States
Prior art keywords
chlordiazepoxide
combination
anxiety
lower alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00190691A
Other languages
English (en)
Inventor
B Beer
D Clody
J Vogel
Z Horovitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of US3784688A publication Critical patent/US3784688A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Definitions

  • the present invention relates to an anti-anxiety combination having substantially no sedative or drowsiness side effects and which includes a chlordiazepoxide-type compound or a pyrazolopyridine carboxylic acid or ester in combination with a xanthine-type compound, such as theophylline or caffeine.
  • benzodiazepines such as chlordiazepoxide or diazepam as tranquilizers and anti-anxiety agents is well-known in the art. These compounds have been found to have remarkable anti-anxiety properties. However, they also have been found to produce significant side effects, namely drowsiness and sedation.
  • the use of chlodiazepoxide, for example, is therefore limited to applications where its sedative side effects will be of little or no concern.
  • chlordiazepoxide would not be indicated for a patient in an anxious state if the patient must drive an automobile or function in any manner where he must be alert. In such cases, other anti-anxiety drugs, possibly less effective than the above mentioned benzodiabepines, would be indicated.
  • chlordiazepoxide-type compounds can be inhibited and in many cases substantially eliminated without adversely affecting their anti-anxiety properties by employing in combination with the chlordiazepoxide-type compounds, xanthine-type compounds.
  • chlordiazepoxide-type anti-anxiety effects can be obtained employing relatively inexpensive xanthine-type drugs in combination with relatively small amounts of the more expensive chlordiazepoxide-type compounds, without the adverse sedative side elfects inherent in the use of the chlordiazepoxide compound alone.
  • antianxiety combinations comprising pyrazolopyridine carboxylic acids or esters and a xanthine-type compound.
  • the pyrazolopyridine compounds which can be employed in the anti-anxiety combinations of the invention can be represented by the structures 3,784,688 Patented Jan. 8, 1974 wherein R is hydrogen, alkyl, or phenyl-lower alkyl, R is lower alkyl, phenyl, phenyl-lower alkyl, R ,R -phenyllower alkyl or cycloalkyl-lower alkyl, R is hydrogen, lower alkyl, phenyl or R ,R -phenyl, Z is or R ,R is hydrogen, lower alkyl, lower alkanoyl or phenyl, R is hydrogen, lower alkyl or lower alkanoyl, R and R each is halogen, lower alkyl or lower alkoxy, X is hydrogen, lower alkyl, hydroxy-lower alkyl, phenyl, R ,R -phenyl, phenyl-lower alkyl or R ,R -pheny
  • Examples of specific pyrazolopyridine compounds which can be employed herein include, but are not limited to, 1 ethyl 4 (isopropylidenehydrazino) lH-pyrazolo [3,4-b]pyridine-S-carboxylic acid, its ethyl ester and its ethyl ester hydrochloride salt, and 4-(butylamino)-1- ethyl-1H-pyrazolo[3,4-b]-pyridine-5-carboxylic acid, ethyl ester.
  • Other pyrazolopyridine compounds suitable for use herein are disclosed in the above-identified copending applications.
  • the chlordiazepoxide-type compounds which can be utilized in the combination of the invention have the generic formula wherein R represents a member of the group consisting of hydrogen, lower alkyl, lower alkenyl, hydroxy-lower alkyl and lower alkoxy-lower alkyl, R represents a member of the group consisting of hydrogen and lower alkyl, R represents a member of the group consisting of phenyl, halo-phenyl, nitrophenyl and lower alkoxyphenyl, R and R each represents a member of the group consisting of hydrogen, halogen and lower alkyl, and acid addition salts thereof.
  • chlordiazepoxide-type compounds which are particularly suitable for use herein include, but are not limited to, ehlordiazepoxide, that is 7-chloro-2- methylamino 5 phenyl-3H-1,4-benzodiazepine 4-oxide,
  • xanthine compounds which can be employed in the combination of the invention have the following structure:
  • R and R are lower alkyl having from 1 to about 8 carbons such as methyl, ethyl, propyl, isopropyl, t-butyl, pentyl, hexyl, Z-methylheptyl, heptyl, octyl and the like.
  • suitable xanthines include 1,3-dimethylxanthine, 3,7 dimethylxanthine and 1,3,7 trimethylxanthine.
  • the combinations of the invention should be formulated to contain a weight ratio of xanthine compound (A) and chlordiazepoxide type compound (B) or pyrazolopyridine compound (C) of within the range of from about 2:1 (A:B or C) to about 15:1 (A:B or C) and preferably from about :1 to about :1.
  • Preferred combinations of the present invention include theophylline or caffeine (A) and chlordiazepoxide (B) in a weight ratio (A:B) to each other ranging from 5 :1 to 10:1, and theophylline or caffeine (A) and 1-ethyl-4-(isopropylidenehydrazino) 1H pyrazolo[3,4 b]pyridine-5- carboxylic acid, ethyl ester hydrochloride (C) in a weight ratio (AzC) to each other ranging from 5:1 to 10:1.
  • the combinations of the invention are useful in the alleviation of anxious states without imparting sedation or drowsiness in mammalian species, such as rats, dogs or cats. They can be formulated in various forms, such as tablet, solutions for interaperitoneal injection, or elixir. and may be administered 1 to 3 times daily to provide a dosage of active ingredients within the range of from about 0.3 mg./ kg. of body weight to 10.0 mg./kg. of body weight with the preferred range being from 1.5 mg./kg. of body weight to about 5.0 mg./kg. of body weight, upon each administration.
  • Suitable carrier materials include, for example, water, gelatin, gum arabic, lactose, starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petroleum jelly, etc.
  • the pharmaceutical preparations can be in solid form (e.g., as tablets, drages, suppositories, capsules); in semisolid form (e.g., as salves) or in liquid form (e.g., as solutions, suspensions or emulsions). They may be sterilized and/or contain additives such as preserving, stabilizing, wetting or emulsifying agents, salts for varying the osmotic pressure or buffers.
  • the aforesaid preparations may further be compounded with other therapeutically valuable substances such as with compounds having antibacterial activity.
  • Holtzman rats Forty naive adult male Holtzman rats (approximately 170 g.) are randomly divided into five groups and deprived of water for 48 hours prior to the test session. Food is available in the home cage at all times.
  • the apparatus is clear Plexiglas box (38 x 38 cm.) with a black Plexiglas compartment (10 x 10.5 cm.) attached to one wall. An opennig (5 x 7.5 cm.) leads from the large box to the small compartment.
  • the entire apparatus has a stainless steel grid floor.
  • a water bottle with a metal drinking tube is fitted to the outside of the small compartment, so that the tube extended 2 cm. (through a 1-cm. hole) into the box at a height of 3 cm. above the grid.
  • a drinkometer circuit is connected between the drinking tube and the grid floor of the apparatus, so that the subject completed the circuit whenever it licked the tube.
  • the apparatus was placed in a quiet area of the laboratory.
  • Shock is administered to each subject by switching the connections to the drinking tube and grids from the drinkometer to a Grason-Stadler Shocker (Model E1064GS) set at 0.5 ma.
  • Grason-Stadler Shocker Model E1064GS
  • each subject is placed in the apparatus. Subject is allowed to find the drinking tube and complete 20 licks before shock (available at the tube for 2 seconds) is administered. The subject controlled shock duration by withdrawing from the tube. A 33-minute times is automatically started at the termination of the first shock. During the 3-minute period, shocks are delivered following each twentieth lick. The number of shocks delivered during the 3-minute session is recorded for each subject and is a direct indication of anti-anxiety effects of the drugs administered. Because the primary interest in the effects of drugs on behavior that is suppressed by punishment, and since motivation under the deprivation conditions imposed in this procedure are maximum, non-shocked animals are not included in these experiments.
  • Drugs are prepared as solutions in distilled water or suspensions in agar so that each cubic centimeter contained 1 kg. of body weight dosage. All statistical comparisons were made using Mann-Whitney U test (twotailed).
  • EXAMPLE 1 The effect of theophylline tht is, 1,3-dimethylxanthine (25 mg./kg.) alone, chloridazepoxide (4.0 mg./kg.) alone and a combination of theophylline and chlordiazepoxide were tested in the rat conflict procedure described above. Saline solution was employed as a control. Test results obtained are set out in Table I below.
  • Theophylline (25 mg./kg.) and chlordiazepoxide (4.0 mg./kg.) 13.25
  • EXAMPLE 2 The effect of theophylline (25 mg./kg.) alone, l-ethyl- 4 (isopropylidenehydrazino) lH-pyrazolo-[3,4-b]-pyridine-S-carboxylic acid, ethyl ester, hydrochloride (hereinafter referred to as pyrazolopyridine) (1 mg. /kg.) alone and a combination of these two drugs in accordance with the invention were tested in the rat conflict procedure described above. Saline solution was employed as a control, Test results obtained are set out in Table II.
  • the administration to rats of the combination of the invention results in a significantly greater number of shocks taken on conflict than when either of theophylline or pyrazolopyridine is administered alone.
  • a method for treating anxiety in an anxious host which comprises administering to the anxious host a composition comprising chlordiazepoxide and caffeine, wherein the weight ratio of caffeine to chlordiazepoxide is from about 2:1 to about 15: 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US00190691A 1971-10-19 1971-10-19 Anti-anxiety combination Expired - Lifetime US3784688A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19069171A 1971-10-19 1971-10-19

Publications (1)

Publication Number Publication Date
US3784688A true US3784688A (en) 1974-01-08

Family

ID=22702367

Family Applications (1)

Application Number Title Priority Date Filing Date
US00190691A Expired - Lifetime US3784688A (en) 1971-10-19 1971-10-19 Anti-anxiety combination

Country Status (3)

Country Link
US (1) US3784688A (enExample)
DE (1) DE2251379A1 (enExample)
FR (1) FR2157892B1 (enExample)

Also Published As

Publication number Publication date
FR2157892A1 (enExample) 1973-06-08
FR2157892B1 (enExample) 1976-05-21
DE2251379A1 (de) 1973-04-26

Similar Documents

Publication Publication Date Title
Vogel et al. A simple and reliable conflict procedure for testing anti-anxiety agents
WO2011161099A1 (de) Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
KR910011802A (ko) 디아자 화합물
US4420483A (en) Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
Maickel et al. Effects of various depressant drugs on deprivation-induced water consumption
Trelinski et al. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms
IL89031A (en) Drugs containing benzamide for the treatment of thought disorders or for their prevention and preparation
US2566200A (en) Oral therapeutic tablets
US3740433A (en) Anti-anxiety composition and method of use
US3784688A (en) Anti-anxiety combination
Siegel et al. The prolonged effects of naloxone on play behavior and feeding in the rat
US3879512A (en) Anti-anxiety combination and method of use
US4404212A (en) Prostacyclin treatment of thrombosis
US5789407A (en) Method of treating depression with certain triazine derivatives
AU656443B2 (en) Pharmaceutical composition for the improvement of dysuria
Thorne The anticonvulsant action of Tridione: preliminary report
US3157574A (en) Method of reducing cholesterol levels
US4189478A (en) Medicinal composition and its use as antidepressive agent
Doust et al. Comparison of cerebral toxicity of monomeric and trimeric forms of sodium iothalamate
JPH10338631A (ja) 抗不安剤
US2916417A (en) Article of manufacture
Reid A comparison of the metabolic pathways of glycine and alanine
US4734412A (en) Medicament
US3541217A (en) Omicron-chlorobenzylaminoguanidine for treating bovine ketosis
US6110915A (en) Antiemetic use of triazolo-pyridazine derivatives